The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

Belski is especially bullish on small- and mid-cap equities, calling them “the golden child of the next decade. I think that ...

GSK and other drugmakers have lost no time in filing an appeal to a Delaware court’s decision to allow more than 70,000 Zantac-related ... wiped billions off its market cap.

Notably, GSK’s previously sold antacid Zantac may have caused cancer in some ... From a valuation perspective, GSK, with a $77.0 billion market cap, is already a pharma giant across several ...

Having removed uncertainty by resolving the vast majority of Zantac litigation cases in the ... The Warwickshire-based firm last month scaled back estimates for 2024 due to supply chain disruption ...

And with no admitted fault or failure, I'm delighted that we've also drawn a line under the vast majority of Zantac litigation ... U.S. were key factors, but market shares for both these vaccines ...

GSK PLC (NYSE:GSK) successfully resolved the majority of Zantac litigation ... The company faces challenges in the Chinese market due to tighter POB budgets and macroeconomic pressures affecting ...

GSK, its consumer health spin-off Haleon, and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it ...

During a news conference, Attanasio predicted the value for Adames in the open market to be “very high ... The Mets have an interest in bringing him back, but other contending clubs will ...